An Evening With the Experts: Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer

Hear from the experts on how the latest clinical data inform the use of biomarkers to assess risk and selection of CDK4/6 inhibitor&ndash based therapy for patients with HR+/HER2- early breast cancer in these downloadable slides and on-demand webcast from a live CCO webinar.

Share

Program Content

No activities added yet

Activities

HR+/HER2- EBC Tx Benefit
Prognostic and Predictive Measures of Therapeutic Benefit in Early Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2021

Expires: June 14, 2022

Adj Tx for HR+/HER2- EBC
Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2021

HR+/HER2- EBC Neoadj Tx
Neoadjuvant Therapy Considerations With CDK4/6 Inhibitors in HR+/HER2- EBC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2021

Expires: June 14, 2022

<i>EP</i>: HR+/HER2- EBC
ExpressPoints:
Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2021

Expires: June 17, 2022

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly